NYSEAMERICAN:AST - Asterias Biotherapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.60 -0.05 (-3.03 %)
(As of 08/19/2018 03:27 AM ET)
Previous Close$1.60
Today's Range$1.55 - $1.70
52-Week Range$1.20 - $3.74
Volume122,914 shs
Average Volume215,293 shs
Market Capitalization$102.89 million
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Asterias Biotherapeutics logoAsterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.

Receive AST News and Ratings via Email

Sign-up to receive the latest news and ratings for AST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:AST
CUSIPN/A
Phone+1-510-4563805

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-403.38%
Return on Equity-79.80%
Return on Assets-59.45%

Miscellaneous

EmployeesN/A
Outstanding Shares55,510,000
Market Cap$102.89 million

Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) posted its quarterly earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The biotechnology company earned $1.75 million during the quarter, compared to the consensus estimate of $2.81 million. Asterias Biotherapeutics had a negative return on equity of 79.80% and a negative net margin of 403.38%. View Asterias Biotherapeutics' Earnings History.

When is Asterias Biotherapeutics' next earnings date?

Asterias Biotherapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 13th 2018. View Earnings Estimates for Asterias Biotherapeutics.

What price target have analysts set for AST?

3 analysts have issued 1-year price targets for Asterias Biotherapeutics' stock. Their forecasts range from $6.00 to $11.00. On average, they anticipate Asterias Biotherapeutics' share price to reach $8.50 in the next year. This suggests a possible upside of 431.3% from the stock's current price. View Analyst Price Targets for Asterias Biotherapeutics.

What is the consensus analysts' recommendation for Asterias Biotherapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Asterias Biotherapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Asterias Biotherapeutics.

What are Wall Street analysts saying about Asterias Biotherapeutics stock?

Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (8/14/2018)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We use a sum-of-the-parts approach, which ascribes a $440M risk-adjusted net present value (rNPV) to the AST-OPC1 program in AST-VAC programs in NSCLC and prostate cancer. Our model involves a 70% probability of success and 16% discount rate for AST-OPC1 in SCI. The total projected firm value is $700M. This translates into a price per share of $11.00 given about 65M fully-diluted shares outstanding as of end-2Q 2019." (8/10/2018)

Are investors shorting Asterias Biotherapeutics?

Asterias Biotherapeutics saw a decrease in short interest in July. As of July 31st, there was short interest totalling 3,279,771 shares, a decrease of 1.2% from the July 13th total of 3,319,891 shares. Based on an average trading volume of 188,126 shares, the days-to-cover ratio is presently 17.4 days. Approximately 10.1% of the company's stock are short sold. View Asterias Biotherapeutics' Current Options Chain.

Who are some of Asterias Biotherapeutics' key competitors?

Who are Asterias Biotherapeutics' key executives?

Asterias Biotherapeutics' management team includes the folowing people:
  • Mr. Michael H. Mulroy, Chief Exec. Officer, Pres & Director (Age 52)
  • Dr. Edward D. Wirth III, M.D., Ph.D., Chief Medical Officer (Age 53)
  • Dr. Katharine E. Spink, Consultant (Age 44)
  • Mr. Stephen L. Cartt, Advisor & Director (Age 55)
  • Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 42)

Has Asterias Biotherapeutics been receiving favorable news coverage?

News articles about AST stock have been trending somewhat positive on Sunday, according to Accern. The research group scores the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Asterias Biotherapeutics earned a news and rumor sentiment score of 0.12 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 47.53 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Asterias Biotherapeutics.

Who are Asterias Biotherapeutics' major shareholders?

Asterias Biotherapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.88%), BlackRock Inc. (0.38%), Creative Planning (0.33%), Paloma Partners Management Co (0.26%), Renaissance Technologies LLC (0.19%) and LMR Partners LLP (0.15%). Company insiders that own Asterias Biotherapeutics stock include Edward Wirth, Katharine E Spink and Michael H Mulroy. View Institutional Ownership Trends for Asterias Biotherapeutics.

Which institutional investors are selling Asterias Biotherapeutics stock?

AST stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. View Insider Buying and Selling for Asterias Biotherapeutics.

Which institutional investors are buying Asterias Biotherapeutics stock?

AST stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Paloma Partners Management Co, Renaissance Technologies LLC, LMR Partners LLP and Creative Planning. View Insider Buying and Selling for Asterias Biotherapeutics.

How do I buy shares of Asterias Biotherapeutics?

Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Asterias Biotherapeutics' stock price today?

One share of AST stock can currently be purchased for approximately $1.60.

How big of a company is Asterias Biotherapeutics?

Asterias Biotherapeutics has a market capitalization of $102.89 million.

How can I contact Asterias Biotherapeutics?

Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.


MarketBeat Community Rating for Asterias Biotherapeutics (NYSEAMERICAN AST)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  183
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.